메뉴 건너뛰기
Chinese Journal of Neurology
Volumn 42, Issue 1, 2009, Pages 6-7
Medication therapy of remit-relapse multiple sclerosis

(1)  Xu, Xian Hao a  

a NONE
Author keywords

[No Author keywords available]
Indexed keywords

EID: 80155171007     PISSN: 10067876     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (1)
References (11)
  • 1
    • 33750579981 scopus 로고    scopus 로고
    • Multiple sclerosis: New insights and trends
    • Inglese M. Multiple sclerosis: new insights and trends. Am J Neuroradiol, 2006, 27: 954-957.
    • (2006) Am J Neuroradiol , vol.27 , pp. 954-957
    • Inglese, M.1
  • 2
    • 44849088841 scopus 로고    scopus 로고
    • Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: A systematic comparison
    • Freedman MS, Hughes B, Mikol DD, et al. Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur Neurol, 2008, 60: 1-11.
    • (2008) Eur Neurol , vol.60 , pp. 1-11
    • Freedman, M.S.1    Hughes, B.2    Mikol, D.D.3
  • 3
    • 39549087978 scopus 로고    scopus 로고
    • Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-la or 1b
    • Baum K, O'Leary C, Coret Ferrer F, et al. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-la or 1b. MultScler, 2007, 13: 1153-1160.
    • (2007) MultScler , vol.13 , pp. 1153-1160
    • Baum, K.1    O'Leary, C.2    Coret Ferrer, F.3
  • 4
    • 34347226688 scopus 로고    scopus 로고
    • Combination therapy for the treatment of multiple sclerosis: Challenges and opportunities
    • Stuart WH. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.Curr Med Res Opin, 2007, 23: 1199-1208.
    • (2007) Curr Med Res Opin , vol.23 , pp. 1199-1208
    • Stuart, W.H.1
  • 5
    • 43149085573 scopus 로고    scopus 로고
    • Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta
    • Farrell R, Kapoor R, Leary S, et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult Scler, 2008, 14: 212-218.
    • (2008) Mult Scler , vol.14 , pp. 212-218
    • Farrell, R.1    Kapoor, R.2    Leary, S.3
  • 6
    • 35448932764 scopus 로고    scopus 로고
    • The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients
    • Gibbs E, Oger J. The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients. J Neuroimmunol, 2007, 190: 146-150.
    • (2007) J Neuroimmunol , vol.190 , pp. 146-150
    • Gibbs, E.1    Oger, J.2
  • 7
    • 39549108366 scopus 로고    scopus 로고
    • Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: A Canadian multiple sclerosis clinic-based study
    • Boz C, Oger J, Gibbs E, et al. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. Mult Scler, 2007, 13: 1127-1137.
    • (2007) Mult Scler , vol.13 , pp. 1127-1137
    • Boz, C.1    Oger, J.2    Gibbs, E.3
  • 8
    • 35448967388 scopus 로고    scopus 로고
    • Identification of interferon-beta antibodies in a reference laboratory setting: Findings for 1144 consecutive sera
    • Prince HE, Lape-Nixon M, Audette C, et al. Identification of interferon-beta antibodies in a reference laboratory setting: findings for 1144 consecutive sera. J Neuroimmunol, 2007, 190: 165-169.
    • (2007) J Neuroimmunol , vol.190 , pp. 165-169
    • Prince, H.E.1    Lape-Nixon, M.2    Audette, C.3
  • 9
    • 48349102333 scopus 로고    scopus 로고
    • Important sources of variability in clinical studies of neutralizing antibodies against interferon beta
    • Hurwitz BJ. Important sources of variability in clinical studies of neutralizing antibodies against interferon beta. J Neurol Sci, 2008, 272: 8-19.
    • (2008) J Neurol Sci , vol.272 , pp. 8-19
    • Hurwitz, B.J.1
  • 10
    • 37249048528 scopus 로고    scopus 로고
    • Pharmacological treatment of early multiple sclerosis
    • Stiive O, Bennett JL, Hemmer B, et al. Pharmacological treatment of early multiple sclerosis. Drugs, 2008, 68: 73-83.
    • (2008) Drugs , vol.68 , pp. 73-83
    • Stiive, O.1    Bennett, J.L.2    Hemmer, B.3
  • 11
    • 84861451293 scopus 로고    scopus 로고
    • Chinese source
    • 2002: 418-421.
    • (2002) , pp. 418-421

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.